Enjoy the structurali nterplay between chemistry and biology! As an organic chemist, you have the tools to create novel small molecules to interact with biological macromolecules, manipulate biological processes, and decipher the underlying molecular principles of diseases. This can ultimately give you the power to treat these indications and help patients.
What are the main challengesi nthe broad area of your research?
Drug discoveryi savery challenging endeavor,a sm ultiple parameterso ft he drug molecule have to be tuned in order to get the optimal candidate for the treatment of ad isease. The discoveryo fn ovel chemical scaffolds represents one of the first big hurdles in ad rugd iscovery program. Here, the de novo designo fn ovel scaffolds is av ery attractive and rewarding alternative to high-throughput screens.T his needs detailed structuralu nderstanding of the biological target molecule and al ot of creative thinkinga bout appropriate smallm olecule counterparts and their synthetic manipulation.
What future opportunities do you see (in the light of the results presented in this paper)?
As matrix metalloproteinases are validated therapeutic targets, but the developmento fm arketed drugs has been hampered so far,t he presented design approachc ould serve as an inspiration for future drug discoverya nd development campaigns in this field. Merging two binding motifs in one inhibitor molecule could also be exploited in the search forn ew modulators of other target proteins.
What other topics are you working on at the moment?
We are working on several aspects of medicinal chemistry.T his includes, amongst others,t he de novo design of drug-like small molecules, natural products, and the synthesis of peptidomimetics. To gether with our academic and industrial partners, we are collaborating on drugd iscoverya nd development projects for av ariety of indications. Currently,w eh ave as trong focus on infectious diseases stretching from antibiotics to parasitic infections, but also diabetes and cancerare indications in our project portfolio.
